Different binding of ¹²⁵I-LPS to plasma proteins from persons with high or low HDL

References

• Cross AS, Opal SM. Endotoxin's role in Gramnegative bacterial infection. Curr Opin Infect Dis 1995; 8: 156–63
   Web of Science ®Google Scholar
• Van der Poll T, Lowry SF. Biological responses to endotoxin in humans. Progr Surg 1995; 20: 18–32
   Google Scholar
• Moran AP. Structure-bioactivity relationships of bacterial endotoxins. J Toximl 1995; 14: 47–83
   Google Scholar
• Read TE, Harris HW, Grunfeld C, Feingold KR, Kane JP, Rapp JH. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Em Heart J 1993; 14: 125–9, Suppl K
   PubMed Web of Science ®Google Scholar
• Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979; 64: 1516–24
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptormediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986; 83: 2704–8
   PubMedGoogle Scholar
• Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61: 5140–6
   PubMed Web of Science ®Google Scholar
• Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86: 696–702
   PubMed Web of Science ®Google Scholar
• Eichbaum EB, Harris HW, Kane JP, Rapp JH. Chylomicrons can inhibit endotoxin activityin vitro. J Surg Res 1991; 51: 413–16
   PubMed Web of Science ®Google Scholar
• Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995; 63: 2041–6
   PubMed Web of Science ®Google Scholar
• Crutchley DJ, McPhee GV, Terris MF, Canossa Tems MA. Levels of three hemostatic factors in relation to serum lipids: monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis 1989; 9: 934–9
   PubMedGoogle Scholar
• Eggesbø JB, Hjennann I, Høstmark AT, Joø GB, Kierulf P. Lipopolysaccharide-induced monocyte procoagulant activity, fibrinopeptide A, and PAI-I levels in persons with high or low levels of HDL-lipoprotein. Thromb Res 1993; 70(2)161–71
   PubMedGoogle Scholar
• Eggesbø JB, Hjermann I, Øvstebø R, Joø GB, Kierulf P. LPS induced procoagulant activity and plasminogen activator activity in mononuclear cells from persons with high or low levels of HDL lipoprotein. Thromb Res 1995; 77: 441–52
   PubMedGoogle Scholar
• Eggesbø JB, Hagve TA, Bersum K, Høstmark AT, Hjermann I, Kierulf P. Lipid composition of mononuclear cell membranes and serum from persons with high or low levels of serum HDL cholesterol. Stand J Clin Lab Invest 1996; 56: 199–210
   PubMed Web of Science ®Google Scholar
• Eggesbø JB, Hjermann I, Høstmark AT, Kierulf P. LPS induced release of IL-1 β, IL-6, IL-8 and TNFα in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL. Cytokine 1996; 8(2)152–60
   PubMedGoogle Scholar
• Leren P, Helgeland A, Hjermann I, Holme I. The Oslo Study: CHD risk factors, socioeconomic influences, and intervention. Am Heart J 1983; 106: 1200–6
   PubMedGoogle Scholar
• Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159: 195–204
   PubMed Web of Science ®Google Scholar
• Hsstmark AT, Lystad E, Spydevold O, Haug A. Estimation of lipoprotein and apoprotein distribution in rat plasma by cumulative density ultra-centrifugation and sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Biochem Med 1984; 31: 54–64
   PubMedGoogle Scholar
• Tobias PS, Ulevitch RJ. Lipopolysaccharidebinding protein and CD14 in the lipopolysaccharide-dependent activation of cells. Chest 1994; 105: 48S–50S
   Google Scholar
• Ulevitch RJ. The preparation and characterization of a radioiodinated bacterial lipopolysaccharide. Immunochemistry 1978; 15: 157–64
   PubMedGoogle Scholar
• Jeppsson JO, Laurell CB, Franzen B. Agarose gel electrophoresis. Clin Chem 1979; 25: 629–638
   PubMed Web of Science ®Google Scholar
• Fujihara Y, Lei MG, Morrison DC. Characterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain. Infect Immun 1993; 61: 910–18
   PubMedGoogle Scholar
• Yentis SM, Gooding RP, Riches PG. The effects of IgG and immune complexes on the endotoxininduced cytokine response. Cytokine 1994; 6: 247–254
   PubMedGoogle Scholar
• Berger D, Beger HG. Comparison of the endotoxin-binding capacity of human transferrin and a human applicable immunoglobulin preparation. Artzneimittelforschung 1988; 38: 817–20
   PubMedGoogle Scholar
• Ogawa Y, Murai T, Kanoh S. Characterization of the pyrogenicity of two different lipopolysaccharides and their lipid A-bovine serum albumin complexes. Journal of Pharmacobio-Dynamics 1986; 9: 722–8
   PubMedGoogle Scholar
• Dziarski R. Cell-bound albumin is the 70-kDa peptidoglycan-, lipopolysaccharide-, and lipoteichoic acid-binding protein on lymphocytes and macrophages. J Biol Chem 1994; 269: 20431–6
   PubMedGoogle Scholar
• Schumann RR, Lamping N, Kirschning C, Knopf HP, Hoess A, Herrmann F. Lipopolysaccharide binding protein: its role and therapeutical potential in inflammation and sepsis. Biochem Soc Trans 1994; 22: 80–2
   PubMedGoogle Scholar
• Durieux J-J, Vita N, Popescu O, Guette F, Calzada-Wack J, Munker R, et al. The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol 1994; 24: 2006–12
   PubMed Web of Science ®Google Scholar
• Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181: 1743–54
   PubMed Web of Science ®Google Scholar
• Pugin J, Ulevitch RJ, Tobias PS. Mechanisms of cellular activation by endotoxin. Prog Surg 1995; 20: 8–17
   Google Scholar
• Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025–35
   PubMed Web of Science ®Google Scholar
• Munford RS, Hall CL, Dietschy JM. Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins. Infect Immun 1981; 34: 835–43
   PubMed Web of Science ®Google Scholar
• Vogelberg KH, Wagner GG. Artefakte der Lipidelektrophorese: Randzonendefekte in Agarosegel. J Clin Chem Clin Biochem 1977; 15: 93–4
   PubMedGoogle Scholar
• Wille LE, Torsvik H, Kierulf P, Gjone E. Studies on the pre-alpha-lipoprotein of human serum. II. Evidence for the presence of an albumin-apo-A-I complex. Scand J Clin Lab Invest 1977; 37: 545–9
   PubMed Web of Science ®Google Scholar
• Eggesbø JB, Hjermann I, Lund PK, Joø GB, Øvstebø R, Kierulf P. LPS-induced release of IL-Iβ, IL-6, IL-8, TNFα and SCD14 in whole blood and PBMC from persons with high or low levels of HDL-lipoprotein. Cytokine 1994; 6: 521–9
   PubMedGoogle Scholar